- Home
- HBIO vs MBRX Comparison
HBIO vs MBRX Comparison
Compare HBIO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- MBRX
- Stock Information
- Founded
- HBIO 1901
- MBRX 2015
- Country
- HBIO United States
- MBRX United States
- Employees
- HBIO N/A
- MBRX N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- HBIO Industrials
- MBRX Health Care
- Exchange
- HBIO Nasdaq
- MBRX Nasdaq
- Market Cap
- HBIO 24.6M
- MBRX 23.5M
- IPO Year
- HBIO 2000
- MBRX 2016
- Fundamental
- Price
- HBIO $0.52
- MBRX $0.47
- Analyst Decision
- HBIO Buy
- MBRX Strong Buy
- Analyst Count
- HBIO 3
- MBRX 4
- Target Price
- HBIO $2.50
- MBRX $5.00
- AVG Volume (30 Days)
- HBIO 17.4M
- MBRX 4.1M
- Earning Date
- HBIO 11-06-2025
- MBRX 11-12-2025
- Dividend Yield
- HBIO N/A
- MBRX N/A
- EPS Growth
- HBIO N/A
- MBRX N/A
- EPS
- HBIO N/A
- MBRX N/A
- Revenue
- HBIO $88,750,000.00
- MBRX N/A
- Revenue This Year
- HBIO N/A
- MBRX N/A
- Revenue Next Year
- HBIO $7.02
- MBRX N/A
- P/E Ratio
- HBIO N/A
- MBRX N/A
- Revenue Growth
- HBIO N/A
- MBRX N/A
- 52 Week Low
- HBIO $0.28
- MBRX $0.25
- 52 Week High
- HBIO $2.82
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- HBIO 58.79
- MBRX 47.49
- Support Level
- HBIO $0.40
- MBRX $0.46
- Resistance Level
- HBIO $0.94
- MBRX $0.54
- Average True Range (ATR)
- HBIO 0.06
- MBRX 0.04
- MACD
- HBIO 0.02
- MBRX -0.00
- Stochastic Oscillator
- HBIO 24.68
- MBRX 32.93
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.